Neonatal Fc Receptor Promotes Immune Complex-mediated Glomerular Disease
Overview
Authors
Affiliations
The neonatal Fc receptor (FcRn) is a major regulator of IgG and albumin homeostasis systemically and in the kidneys. We investigated the role of FcRn in the development of immune complex-mediated glomerular disease in mice. C57Bl/6 mice immunized with the noncollagenous domain of the α3 chain of type IV collagen (α3NC1) developed albuminuria associated with granular capillary loop deposition of exogenous antigen, mouse IgG, C3 and C5b-9, and podocyte injury. High-resolution imaging showed abundant IgG deposition in the expanded glomerular basement membrane, especially in regions corresponding to subepithelial electron dense deposits. FcRn-null and -humanized mice immunized with α3NC1 developed no albuminuria and had lower levels of serum IgG anti-α3NC1 antibodies and reduced glomerular deposition of IgG, antigen, and complement. Our results show that FcRn promotes the formation of subepithelial immune complexes and subsequent glomerular pathology leading to proteinuria, potentially by maintaining higher serum levels of pathogenic IgG antibodies. Therefore, reducing pathogenic IgG levels by pharmacologic inhibition of FcRn may provide a novel approach for the treatment of immune complex-mediated glomerular diseases. As proof of concept, we showed that a peptide inhibiting the interaction between human FcRn and human IgG accelerated the degradation of human IgG anti-α3NC1 autoantibodies injected into FCRN-humanized mice as effectively as genetic ablation of FcRn, thus preventing the glomerular deposition of immune complexes containing human IgG.
The fate of immune complexes in membranous nephropathy.
Xu J, Hu H, Sun Y, Zhao Z, Zhang D, Yang L Front Immunol. 2024; 15:1441017.
PMID: 39185424 PMC: 11342396. DOI: 10.3389/fimmu.2024.1441017.
Exploiting the neonatal crystallizable fragment receptor to treat kidney disease.
Dylewski J, Haddad G, Blaine J Kidney Int. 2024; 105(1):54-64.
PMID: 38707675 PMC: 11068363. DOI: 10.1016/j.kint.2023.09.024.
The therapeutic age of the neonatal Fc receptor.
Pyzik M, Kozicky L, Gandhi A, Blumberg R Nat Rev Immunol. 2023; 23(7):415-432.
PMID: 36726033 PMC: 9891766. DOI: 10.1038/s41577-022-00821-1.
Anti-phospholipase A2 receptor antibodies directly induced podocyte damage .
Li Y, Yu J, Wang M, Cui Z, Zhao M Ren Fail. 2022; 44(1):304-313.
PMID: 35333675 PMC: 8959519. DOI: 10.1080/0886022X.2022.2039705.
Borza C, Bolas G, Zhang X, Monroe M, Zhang M, Meiler J Front Cell Dev Biol. 2022; 10:836797.
PMID: 35309920 PMC: 8928223. DOI: 10.3389/fcell.2022.836797.